Opinion|Videos|February 21, 2025
KRAS G12 Inhibitor Treatment Options
This video segment examines strategies for managing adverse events associated with adagrasib, comparing its safety profile to other RAS GTPase inhibitors like sotorasib, and discusses key differences, benefits, and risks that may influence treatment selection or consideration of clinical trials.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some strategies you might consider when treating AEs seen with adagrasib? Which AEs are of greatest concern?
- How do the AEs reported in clinical trial for adagrasib compare with other inhibitors of the RAS GTPase family, like sotorasib and others currently under investigation?
- What are some differences between adagrasib and sotorisib? What are some potential risks or benefits that may lead you to choose one of these over the other?
- When might you consider a clinical trial?
Advertisement
Related to this article
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Advertisement
Advertisement
Trending on CancerNetwork
1
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
2
Contextualizing MRD Negativity and PFS Across Treatment Regimens in Relapsed/Refractory Multiple Myeloma
3
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
4
What Sustained MRD Negativity Can Settle About Stopping Myeloma Maintenance
5